Inovo Inc, Naples, Fla, which purchased the oxygen conserving assets and the right to market under the name CHAD Therapeutics, issued a statement to clarify that the company is in no way affiliated with CHAD Therapeutics Inc, Chatsworth, Cailf, which recently announced the suspension of its operations.
Inovo acquired CHAD Therapeutics’ oxygen conserving assets in February 2008 and relocated the manufacturing, sales, and marketing functions for the oxygen conserving assets to Florida in June.
“We continue to emphasize our commitment to both the delivery of high-quality, clinically effective oxygen conservers and the growth of our business for many years to come,” says George Harris, chief executive officer of Inovo.
